
Neuren Pharmaceuticals Limited Investor Relations Material
Latest events

AGM 2025
Neuren Pharmaceuticals Limited

Investor Presentation
26 Aug, 2025

H1 2025
26 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neuren Pharmaceuticals Limited
Access all reports
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing new therapies for neurodevelopmental disorders, including conditions that manifest in early childhood and are characterized by impaired brain cell connections and signaling. The company has a deep expertise in the field, accumulated through extensive clinical development efforts. Neuren Pharmaceuticals has gained recognition for developing the FDA-approved treatment, DAYBUE™ (trofinetide), specifically for Rett syndrome, marking a significant advancement in the treatment of this condition. Furthermore, the company is advancing its research and development pipeline with therapies aimed at addressing a range of neurodevelopmental disorders. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.
Key slides for Neuren Pharmaceuticals Limited


AGM 2025
Neuren Pharmaceuticals Limited


AGM 2025
Neuren Pharmaceuticals Limited
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
NEU
Country
🇦🇺 Australia